Skip to the answer

Mifepristone (Korlym)

Korlym (mifepristone) is a cortisol receptor blocker used to control high blood sugar caused by Cushing's syndrome in adults who can't have or haven't benefited from surgery.

Brand name Mifeprex
Drug class Progestin Antagonist
Rx
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 8, 2026
🧬 Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 8, 2026
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Korlym (mifepristone) is a specialist medicine for high blood sugar caused by Cushing's syndrome (too much cortisol), usually when surgery is not an option or has not worked; it blocks cortisol's receptor and blocks progesterone. Nausea, tiredness and headache are what people most often notice, and low potassium is common, so expect regular blood checks. The boxed warning is that it will end a pregnancy, so pregnancy must be ruled out first and prevented with non-hormonal contraception until a month after stopping. Since it raises cortisol levels, labs cannot catch too little cortisol effect, so unusual weakness, extreme tiredness or nausea means stopping it and getting help at once.

Clinical pearls

  • Take it with a meal every time, and swallow the tablet whole without splitting, crushing or chewing.
  • Hormonal birth control pills, patches and rings do not work reliably with it, so use a copper IUD or barrier method.
  • Simvastatin and lovastatin cannot be combined with it, and certain antifungals, antibiotics and rifampin also clash, so tell every prescriber.
  • If you stop it for more than 14 days, you need a new pregnancy test before restarting.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Korlym will terminate a pregnancy. Because it blocks progesterone — a hormone essential for maintaining pregnancy — taking it while pregnant will cause pregnancy loss. This is the most critical safety concern with this medication.

Before starting Korlym, you must have a negative pregnancy test. While taking it, and for one month after stopping, you must use a reliable non-hormonal form of contraception (such as a copper IUD or barrier methods) unless you have had surgical sterilization. If treatment is paused for more than 14 days, another pregnancy test is required before restarting. Hormonal birth control (pills, patch, ring) does not work reliably with this medication and must not be used.

Read the full warning on DailyMed →
How you get itPrescription only
Earliest FDA record2000
FDA label last updatedSep 25, 2025
FDA’s strongest warning (boxed)Yes, read the warning

Patient Information Guide A plain-language walkthrough of Mifepristone (Korlym), written from its FDA label.

What Mifepristone (Korlym) Is Used For

▾

Korlym is approved for adults with endogenous Cushing's syndrome who have high blood sugar (type 2 diabetes or glucose intolerance) and cannot have surgery or haven't improved with it.

  • Controls high blood sugar caused by excess cortisol in Cushing's syndrome
  • Used when surgery has failed or isn't an option
  • Not for treating ordinary type 2 diabetes unrelated to Cushing's syndrome

How Mifepristone (Korlym) Works

▾

The body has special docking sites called glucocorticoid receptors that cortisol normally latches onto. In Cushing's syndrome, too much cortisol keeps activating these receptors, driving blood sugar dangerously high. Korlym blocks these receptors so cortisol can't connect to them — reducing its harmful effects on blood sugar. At lower doses, it also blocks progesterone receptors, which is why it can end a pregnancy and why strict contraception is required.

Because Korlym blocks the receptor rather than lowering cortisol itself, cortisol levels in the blood actually rise during treatment. This means standard cortisol blood tests cannot be used to judge whether you're getting the right amount of effect from the drug — your doctor will rely on symptoms and other markers instead.

Mifepristone (Korlym) Dosage

▾

Korlym is taken once daily by mouth, always with a meal — food significantly increases how much of the drug your body absorbs, so consistency matters. Swallow the tablet whole; do not split, crush, or chew it.

  • Your prescriber will start at a lower dose and increase gradually, no more than once every 2–4 weeks
  • Dose adjustments are based on how well your blood sugar improves and how well you tolerate the medication
  • Lower maximum doses apply if you have kidney or liver problems, or if you take certain other medications

If you miss a dose, follow your prescriber's guidance — do not double up without being told to.

Dosing details from the FDA-approved label

From the Mifepristone (Korlym) prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

Based on clinical response and tolerability, the dose may be increased in 300 mg increments to a maximum of 1200 mg once daily.

Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Obtain a negative pregnancy test in females of reproductive potential prior to initiating treatment with KORLYM or if treatment is interrupted for more than 14 days. ( 2.1 ) Administer once daily orally with a meal ( 2.2 ). The recommended starting dose is 300 mg once daily ( 2.2 ). Based on clinical response and tolerability, the dose may be increased in 300 mg increments to a maximum of 1200 mg once daily. Do not exceed 20 mg/kg per day ( 2.2 ). Renal impairment: do not exceed 600 mg once daily ( 2.3 ). Mild-to-moderate hepatic impairment: do not exceed 600 mg once daily. Do not use in severe hepatic impairment ( 2.4 ). Concomitant administration with strong CYP3A inhibitors: Do not exceed 900 mg once daily ( 2.5 ). 2.1 Testing Prior to and During KORLYM Administration Obtain a negative pregnancy test in females of reproductive potential prior to initiating treatment with KORLYM or if treatment is interrupted for more than 14 days [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.1 , 8.3 )]. 2.2 Adult Dosage The recommended starting dose is 300 mg orally once daily. KORLYM must be given as a single daily dose. KORLYM should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush, or chew tablets. Dosing and titration The daily dose of KORLYM may be increased in 300 mg increments. The dose of KORLYM may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on a clinical assessment of tolerability and degree of improvement in Cushing's syndrome manifestations. Changes in glucose control, anti-diabetic medication requirements, insulin levels, and psychiatric symptoms may provide an early assessment of response (within 6 weeks) and may help guide early dose titration. Improvements in cushingoid appearance, acne, hirsutism, striae, and body weight occur over a longer period of time and, along with measures of glucose control, may be used to determine dose changes beyond the first 2 months of therapy. Careful and gradual titration of KORLYM accompanied by monitoring for recognized adverse reactions [ See Warnings and Precautions ( 5.1 ) and ( 5.2 ) ] may reduce the risk of severe adverse reactions.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Mifepristone (Korlym) Side Effects

▾

The most commonly reported side effects in clinical studies included:

Common side effects

  • Nausea or vomiting
  • Fatigue
  • Headache
  • Low potassium (which can cause muscle weakness)
  • Joint pain (arthralgia)
  • Swelling in the legs or feet (peripheral edema)
  • Dizziness
  • Decreased appetite
  • Low potassium levels (can cause muscle weakness or cramps)
  • High blood pressure
  • Thickening of the uterine lining (in women)

When to get medical help

  • Signs of adrenal insufficiency (low cortisol effect): unusual weakness, severe nausea, extreme fatigue, low blood pressure, or low blood sugar — stop the medication and seek care immediately
  • Severe low potassium: muscle cramps, weakness, or irregular heartbeat
  • Unexpected or unusual vaginal bleeding
  • Signs of a prolonged QT interval (a heart rhythm problem): palpitations, fainting, or irregular heartbeat
  • If you think you might be pregnant — stop the medication and contact your doctor right away

More serious reactions — including signs of adrenal insufficiency (severe weakness, nausea, low blood pressure, low blood sugar) or significant vaginal bleeding — require stopping the medication and getting medical help right away.

Mifepristone (Korlym) Warnings and Precautions

▾
  • Adrenal insufficiency: Korlym blocks cortisol's effects, so even though your cortisol blood level rises, your body may not be getting enough cortisol activity. Symptoms include profound weakness, severe nausea, extreme fatigue, low blood pressure, and low blood sugar. If this happens, stop Korlym immediately and seek emergency care. High doses of glucocorticoid medication may be needed to counteract the blockade.
  • Low potassium (hypokalemia): Occurred in nearly half of patients in clinical studies. Potassium must be corrected before starting Korlym, and levels should be checked regularly during treatment.
  • Vaginal bleeding and uterine changes: Women may experience unexpected vaginal bleeding or a thickening of the uterine lining. Extra caution is needed if you have a bleeding disorder or take blood thinners.
  • Heart rhythm (QT prolongation): Korlym can lengthen the QT interval — an electrical measurement in the heart. Avoid combining it with other drugs that do the same, and tell your doctor about any heart rhythm conditions.
  • Pregnancy termination: This is an absolute contraindication — see the boxed warning above.

Mifepristone (Korlym) Interactions

▾

Korlym affects the way many other drugs are broken down in the body, and several combinations are either forbidden or require dose adjustments.

  • Simvastatin and lovastatin: Cannot be combined — Korlym dramatically increases their levels, raising the risk of serious muscle breakdown (rhabdomyolysis)
  • Narrow-range drugs (cyclosporine, fentanyl, pimozide, quinidine, tacrolimus, sirolimus, ergotamine, dihydroergotamine): Contraindicated — Korlym raises their levels to potentially dangerous heights
  • Strong CYP3A inhibitors (e.g., certain antifungals or antibiotics): Increase Korlym's own blood levels; use only when necessary with a dose cap
  • CYP3A inducers (e.g., rifampin): Should not be used with Korlym — they reduce its effectiveness
  • Hormonal contraceptives: Cannot be used with Korlym; switch to non-hormonal contraception
  • Bupropion and efavirenz: Use cautiously — Korlym may alter their levels in the body
  • Other CYP3A or CYP2C8/2C9 substrates: Use the lowest effective dose of those medications when combined with Korlym

Interactions listed in the FDA-approved label

From the Mifepristone (Korlym) prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should elapse after cessation of KORLYM before initiating or increasing the dose of any interacting concomitant medication. Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with KORLYM ( 7.1 ).

Read the label’s full interactions text

7 DRUG INTERACTIONS Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should elapse after cessation of KORLYM before initiating or increasing the dose of any interacting concomitant medication. Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with KORLYM ( 7.1 ). CYP3A inhibitors: Caution should be used when KORLYM is used with strong CYP3A inhibitors. Limit mifepristone dose to 900 mg per day when used with strong CYP3A inhibitors ( 7.2 ). CYP3A inducers: Do not use KORLYM with CYP3A inducers ( 7.3 ). Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with KORLYM ( 7.4 ). Drugs metabolized by CYP2B6: Use of KORLYM should be done with caution with bupropion and efavirenz ( 7.5 ). Hormonal contraceptives: Do not use with KORLYM ( 7.6 ). 7.1 Drugs Metabolized by CYP3A Because KORLYM is an inhibitor of CYP3A, concurrent use of KORLYM with a drug whose metabolism is largely or solely mediated by CYP3A is likely to result in increased plasma concentrations of the drug. Discontinuation or dose reduction of such medications may be necessary with KORLYM co-administration. KORLYM increased the exposure to simvastatin and simvastatin acid significantly in healthy subjects. Concomitant use of simvastatin or lovastatin is contraindicated because of the increased risk of myopathy and rhabdomyolysis. [See Contraindications (4.2), Clinical Pharmacology 12.3 ] The exposure of other substrates of CYP3A with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, may be increased by concomitant administration with KORLYM. Therefore, the concomitant use of such CYP3A substrates with KORLYM is contraindicated.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿151 supplements and herbs with documented Mifepristone (Korlym) interactions, ranked by severity Check Mifepristone (Korlym) against a supplement or herb →

Before Taking Mifepristone (Korlym)

▾
  • Pregnancy: Absolutely cannot take Korlym — it will cause pregnancy loss
  • Women of reproductive potential: Must have a negative pregnancy test before starting; must use non-hormonal contraception throughout treatment and for one month after stopping
  • History of unexplained vaginal bleeding, endometrial cancer, or atypical endometrial hyperplasia: Cannot take Korlym
  • Taking systemic corticosteroids for a life-threatening reason (e.g., post-transplant immunosuppression): Cannot take Korlym — it would block those medications' effects
  • Allergy to mifepristone or any ingredient in Korlym: Cannot take it
  • Low potassium: Must be corrected before starting
  • Kidney impairment: A lower maximum daily dose applies — discuss with your prescriber
  • Liver impairment: A lower dose limit applies for mild-to-moderate liver disease; Korlym should not be used at all with severe hepatic impairment

Mifepristone (Korlym) Overdose

▾

There is no documented clinical experience with Korlym overdose at this time. If you or someone else has taken more than prescribed, contact Poison Control (1-800-222-1222) or go to the nearest emergency room right away. Do not wait for symptoms to develop.

What Mifepristone (Korlym) Does in the Body

▾

Korlym blocks the glucocorticoid receptor (the target that cortisol normally binds to), preventing cortisol from producing its usual effects on blood sugar and metabolism. Because the receptor is blocked rather than cortisol itself being reduced, the body's feedback system responds by producing even more cortisol — so blood cortisol levels rise during treatment, even as their harmful effects are suppressed. Mifepristone and its active breakdown products all bind to the glucocorticoid receptor more strongly than cortisol itself does, making the blockade highly effective.

How Your Body Processes Mifepristone (Korlym)

▾

Korlym is taken by mouth and reaches peak blood levels within 1–4 hours. It should always be taken with food, because food significantly increases absorption and helps keep levels consistent from day to day. The drug is heavily protein-bound in the bloodstream and reaches steady, stable levels in the body within about two weeks.

Korlym has a long half-life of roughly 85 hours, meaning it stays active in the body for several days after the last dose — an important consideration when adjusting other medications. It is broken down mainly by the liver (via the CYP3A4 enzyme) into three active metabolites, and about 90% of the drug is eliminated through the stool.

How to Store Mifepristone (Korlym)

▾

Store at controlled room temperature, 25 °C (77 °F); excursions permitted to 15 to 30 °C (59 – 86 °F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

151

Supplements & Herbs That Interact With Mifepristone (Korlym)

151 supplements and herbal products have documented interactions with Mifepristone (Korlym) in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 104
  • Minor · 39
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major +143 more
Every supplement checked against Mifepristone (Korlym) — ranked by severity The full interaction hub: 8 major · 104 moderate · 39 minor · every one linked to its full report. Check Mifepristone (Korlym) against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Mifepristone (Korlym): Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Mifepristone (Korlym) — the kind of thing our pharmacy team would talk through with you at the counter.

Why am I taking this for Cushing's syndrome — isn't mifepristone the abortion pill?

▾
That's a really common question, and it makes sense to ask. Mifepristone does have more than one use. At the higher doses used in Korlym, it blocks cortisol's receptor — which is what helps control blood sugar in Cushing's syndrome. The brand name Korlym is specifically approved for that purpose. It's a completely different context from its use in ending a pregnancy, though the pregnancy risk is very real and serious, which is why strict pregnancy prevention is required while you're taking it.

Why do I have to take it with food every time?

▾
Food actually increases how much of the medication your body absorbs, and it helps keep those levels steady from day to day. If you take it on an empty stomach sometimes and with food other times, your drug levels could bounce around — and that inconsistency can affect how well it works. So pick a meal that's part of your daily routine and stick with it. Think of it like a rule, not just a suggestion.

What does adrenal insufficiency mean, and how will I know if it's happening to me?

▾
Adrenal insufficiency basically means your body isn't getting enough cortisol activity — even though your blood cortisol level is actually high while on Korlym. Because the drug blocks cortisol from working, the effect can sometimes be too strong. Watch for unusual, sudden weakness, extreme tiredness, nausea, feeling faint, or low blood sugar. If those hit you, stop the medication and get medical help right away — don't wait it out. It's rare but serious, and your care team will be monitoring you for it.

What kind of birth control can I use while I'm on Korlym?

▾
You need to use non-hormonal contraception — meaning no birth control pills, patches, hormonal IUDs, injections, or vaginal rings. Korlym can interfere with how those work, and they're not safe or reliable options here. Good non-hormonal choices include a copper IUD or barrier methods like condoms. If you've had a surgical sterilization, you're covered. Your doctor will also need a negative pregnancy test before you start, and you'll need to keep up contraception for at least one month after stopping Korlym.

Are there medications I absolutely cannot take at the same time?

▾
Yes — and this is really important. Korlym affects how the body processes many drugs, sometimes to a dangerous degree. You can't take it with simvastatin or lovastatin (common cholesterol medications), or with drugs like cyclosporine, fentanyl, tacrolimus, pimozide, quinidine, sirolimus, or ergotamine. Hormonal birth control also can't be combined with it. Make sure every doctor and pharmacist you see knows you're on Korlym, because even after you stop taking it, it stays in your system for days and can still interact with new medications you start.

My doctor mentioned my potassium needs monitoring. Why?

▾
Low potassium — called hypokalemia — was actually one of the most common problems seen in people taking Korlym in clinical studies, affecting nearly half of patients. Low potassium can cause muscle weakness, cramps, and in serious cases, heart rhythm issues. Your doctor will check your potassium levels before you start and then periodically throughout treatment, especially after any dose increase. If your levels drop, you may need to take a potassium supplement. Don't ignore symptoms like unusual muscle weakness or cramping — let your care team know.

Is Mifepristone (Korlym) available over the counter?

▾
No. Mifepristone (Korlym) is a prescription medicine: every Mifepristone (Korlym) product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Mifepristone (Korlym) first available?

▾
The earliest FDA record we hold for Mifepristone (Korlym) is from 2000: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Mifepristone (Korlym) was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More About Mifepristone (Korlym) on HelloPharmacist

📊Mifepristone (Korlym) supplement interactions151 checked — ranked by severity 🌿Drug & Supplement CheckerMifepristone (Korlym) vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Mifepristone (Korlym) NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed Data & References for Mifepristone (Korlym) Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Mifepristone (Korlym) on the U.S. Market: Products, Makers and Brands

How Mifepristone (Korlym) appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

The FDA lists Mifepristone (Korlym) products; the earliest marketing or approval year on record is 2000. Brand names on the directory include Mifeprex; the rest are generics.

2000
Earliest FDA record ⓘ

How Widely Mifepristone (Korlym) Is Used (Medicaid Data)

A general measure of how commonly Mifepristone (Korlym) is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Mifepristone (Korlym) is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

2,590
Medicaid prescriptions filled (Q1–Q4 2025)
$46.5M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Mifepristone (Korlym) prescribed? Of the 1,603 medications we measure, Mifepristone (Korlym) ranks #1,152 by Medicaid prescriptions — more than 28% of them.

Where Mifepristone (Korlym) ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,152 of 1,603
#1,147 Ibrutinib 2,698 Rx #1,148 Canagliflozin / Metfor... 2,694 Rx #1,149 Phenol 2,689 Rx #1,150 Dabrafenib 2,673 Rx #1,151 Prasterone Vaginal 2,624 Rx #1,152 Mifepristone (Mifeprex... 2,590 Rx #1,153 Mifepristone (Korlym) 2,590 Rx #1,154 Deferiprone 2,586 Rx #1,155 Calcifediol 2,586 Rx #1,156 Ponatinib 2,562 Rx #1,157 Lanadelumab-flyo injec... 2,560 Rx

Utilization by Mifepristone (Korlym) product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 300 mg oral tablet is the most-dispensed Mifepristone (Korlym) product — about 55% of these Medicaid prescriptions.

mifepristone 300 MG Oral Tablet Most dispensed

1,415 Medicaid prescriptions (Q1–Q4 2025) 55% of Mifepristone (Korlym) prescriptions shown $46.2M gross reimbursement (before rebates) ≈ $32,680 per prescription (gross)

Summed across the 3 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1245262

mifepristone 200 MG Oral Tablet

1,175 Medicaid prescriptions (Q1–Q4 2025) 45% of Mifepristone (Korlym) prescriptions shown $223,230 gross reimbursement (before rebates) ≈ $190 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311704

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mifepristone (Korlym), and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 7 listed Mifepristone (Korlym) NDCs with Medicaid activity.

Mifepristone (Korlym) Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Mifepristone recalls since July 2021.

✅No Mifepristone recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Mifepristone (Korlym) RxCUI 6964 1 dose form · 2 strengths
  1. Dose form (SCDF) Oral Tablet RxCUI 374644 No current FDA listing
    Clinical drug / strength (SCD) 200 MG RxCUI 311704 300 MG RxCUI 1245262

Look up RxCUI 6964 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Mifepristone (Korlym) Brand Names

Mifepristone (Korlym) is sold under one brand name in the FDA directory — Mifeprex. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Mifeprex

Mifepristone (Korlym) Drug Class (RxNorm)

Mifepristone (Korlym) belongs to the Progestin Antagonist class.

Pharmacologic class Progestin Antagonist
Drug family (ATC) Progesterone receptor modulators
How it works Progestational Hormone Receptor Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for This Mifepristone (Korlym) Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Sep 25, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Mifepristone (Korlym).
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Mifepristone (Korlym) after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Linked representative label ⓘ
Corcept Therapeutics Incorporated
Linked label effective
Sep 25, 2025
Composite sections available
23
Linked SPL Set ID
542f3fae-8bc8-4f00-9228-e4b66c9ad6a9
Linked SPL Document ID
f9fd7845-859c-49d4-a1f9-b96b591c4021
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Corcept Therapeutics Incorporated is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →